KH-CB19 - CAS 1354037-26-5
Catalog number: 1354037-26-5
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C15H13Cl2N3O2
Molecular Weight:
338.19
COA:
Inquire
Targets:
CDK
Description:
KH-CB19, a CLK1/CLK4 inhibitor, has been found to probably restrain the phosphorylation of serine- and arginine-rich (SR) proteins. IC50: 20 nM for CLK1.
Purity:
98%
Appearance:
Powder
Synonyms:
KH-CB19; KH CB19; KHCB19. Ethyl 3-[(E)-2-Amino-1-Cyanoethenyl]-6,7-Dichloro-1-Methyl-1h-Indole-2-Carboxylate; 2wu7; GTPL8055; 3761AH
Solubility:
10 mM in DMSO
Storage:
-20ºC Freeze
MSDS:
Inquire
Application:
KH-CB19 is a CLK1/CLK4 inhibitor that has been found to probably restrain the phosphorylation of serine- and arginine-rich (SR) proteins.
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly
Quantity:
Milligrams-Grams
InChIKey:
CXJCGSPAPOTTSF-VURMDHGXSA-N
InChI:
InChI=1S/C15H13Cl2N3O2/c1-3-22-15(21)14-11(8(6-18)7-19)9-4-5-10(16)12(17)13(9)20(14)2/h4-6H,3,18H2,1-2H3/b8-6-
Canonical SMILES:
CCOC(=O)C1=C(C2=C(N1C)C(=C(C=C2)Cl)Cl)C(=CN)C#N
1.Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease.
Jain P;Karthikeyan C;Moorthy NS;Waiker DK;Jain AK;Trivedi P Curr Drug Targets. 2014 May;15(5):539-50.
The cdc2-like kinases (CLKs) are an evolutionarily conserved group of dual specificity kinases belonging to the CMGC (cyclin-dependent kinases (CDKs), mitogen-activated protein kinases (MAP kinases), glycogen synthase kinases (GSK) and CDK-like kinases). The CLK family consists of four isoforms namely CLK1, CLK2, CLK3 and CLK4. The human CLK1 encoded protein comprises 454 amino acids and the catalytic domain of CLK1 exhibits the typical protein kinase fold. CLK1 has been shown to autophosphorylate on serine, threonine and tyrosine residues and phosphorylate exogenous substrates on serine and threonine residues. CLK1 plays an important role in the regulation of RNA splicing through phosphorylation of members of the serine and arginine-rich (SR) family of splicing factors. CLK1 is involved in the pathophysiology of Alzheimer's disease by phosphorylating the serine residue in SR proteins. Nuclear speckles of the nucleoplasm contain the stored form of SR proteins and are moderately responsible for the choice of splicing sites during pre-mRNA splicing. Hence, the inhibition of CLK1 can be used as a therapeutic strategy for Alzheimer's disease. Many natural and synthetic molecules are reported to possess CLK1 inhibitory activity.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related CDK Products


Aloisine B
(CAS: 496864-14-3)

Aloisine B is a potent and selective CDK and GSK-3 inhibitor with highest affinity targets: Glycogen Synthase Kinase-3, Beta (Rattus norvegicus (rat)) (IC50=750...

CAS 667463-62-9 BIO

BIO
(CAS: 667463-62-9)

BIO (6-bromoindirubin-3'-oxime) is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3α/β, shows >16-fold selectivity over CDK5, also a pan-JAK inhibitor.

CAS 1263369-28-3 CDK9-IN-2

CDK9-IN-2
(CAS: 1263369-28-3)

CDK9-IN-2 is a novel cyclin-dependent kinase 9(CDK9) inhibitor.

ON123300
(CAS: 1357470-29-1)

ON123300, a dihydropyrido[2,3-d]pyrimidine derivative, has been found to be an effective multikinase inhibitor that could be probably used against brain tumor a...

CAS 186692-46-6 Seliciclib

Seliciclib
(CAS: 186692-46-6)

Seliciclib is an orally bioavailable, small-molecule cyclin-dependent kinase (CDK) inhibitor with potential proapoptotic and antineoplastic activities. Selicicl...

CAS 1421693-22-2 CDKI-73

CDKI-73
(CAS: 1421693-22-2)

CDKI-73 was cytotoxic to all of the CLL samples tested (n = 38) with a mean LD50 value of 0.08μM ± 0.10 μM following exposure to drug for 48h. In contrast, norm...

AU-12122

AU-12122 is a novel-developed CDK7 inhibitor, which is potent and orally bioactive. It induces apoptosis of acute monocytic leukemia THP-1.

CAS 1374639-75-4 LEE011 succinate

LEE011 succinate
(CAS: 1374639-75-4)

LEE011 is an orally bioavailable and highly specific CDK4/6 (cyclin-dependent kinase 4/6) inhibitor. LEE011 in combination with LGX818 (a V600E BRAF specific in...

Quick Inquiry

Verification code

Featured Items